Oral Transmucosal Drugs Market Report, Global, 2024

The oral transmucosal drugs market size has grown strongly in recent years. It will grow from $36.34 billion in 2023 to $39.7 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth observed in the historic period can be attributed to several factors, including advancements in diagnostic capabilities leading to increased detection and diagnosis rates, an aging demographic that requires more targeted healthcare solutions, environmental pollutants and genetic susceptibilities contributing to the prevalence of certain health conditions, faster relief facilitated by the rapid absorption of drugs through oral transmucosal routes, and improved adherence to treatment regimens due to the convenience and effectiveness of these medications.

The oral transmucosal drugs market size is expected to see strong growth in the next few years. It will grow to $56.83 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth in the forecast period can be attributed to several significant factors, including advancements in personalized medicine leading to tailored treatments for individuals, increasing research focused on developing novel drug delivery systems for improved efficacy and patient experience, the expanding geriatric population necessitating specialized healthcare solutions, growing awareness of oral health leading to demand for oral transmucosal drugs, a rising preference for non-invasive treatment options among patients, and evolving regulatory landscapes shaping the pharmaceutical industry. Major trends expected in this period encompass the adoption of novel formulations for oral transmucosal drugs, personalized medicine approaches that customize treatments based on genetic and physiological factors, advancements in telehealth services facilitating remote patient monitoring and consultations, the integration of digital health technologies in pharmaceutical practices for enhanced patient care and management, and ongoing technological innovations in drug development and delivery systems.

The growth of the oral transmucosal drug market is expected to be driven by the increasing incidence of Parkinson's disease. Parkinson's disease is a progressive neurological disorder characterized by tremors, stiffness, and movement difficulties due to a decline in dopamine-producing cells in the brain. Factors contributing to the rising prevalence of Parkinson's disease include aging populations, environmental pollutants, genetic vulnerabilities, and improved diagnostic capabilities that enhance detection rates. Oral transmucosal drugs play a crucial role in supporting Parkinson's disease treatment by enabling rapid drug absorption and overcoming digestive challenges, resulting in quicker relief, improved adherence, and potentially fewer motor complications. For example, the Parkinson's Foundation reported that approximately 1 million individuals in the United States currently have Parkinson's disease, expected to rise to 1.2 million by 2030. This trend underscores how the increasing incidence of Parkinson's disease is fueling the expansion of the oral transmucosal drug market.

Leading companies in the oral transmucosal drug market are focused on developing innovative drug delivery solutions, such as sublingual vitamin sprays, to enhance drug delivery efficiency, enhance patient convenience, and optimize therapeutic outcomes. A sublingual vitamin spray is a drug delivery system that delivers vitamins directly into the bloodstream through the mucous membranes under the tongue, bypassing the gastrointestinal tract and liver metabolism for rapid and efficient absorption. For instance, Vestige Marketing introduced Absorvit in October 2022, a sublingual vitamin spray that offers swift absorption and rapid results, providing 3-10 times greater absorption than traditional oral methods. It contains upgraded forms and precise doses of essential vitamins, including B12, C, D, and multivitamins, ensuring optimal nutrient delivery for improved wellness.

In January 2024, XOMA Corporation acquired DSUVIA from Talphera, Inc. for $8 million, aiming to capitalize on revenue from DSUVIA, a sufentanil sublingual tablet, while collaborating with Talphera and leveraging potential milestones from Alora Pharmaceuticals in the development of oral transmucosal drugs. Talphera Inc. is a pharmaceutical company involved in oral transmucosal drug development.

Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd, Wockhardt Ltd.

North America was the largest region in the oral transmucosal drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral transmucosal drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oral transmucosal drugs are medications designed to be absorbed through the mucous membranes in the mouth, offering rapid effects while bypassing initial metabolism in the liver and gastrointestinal tract. These drugs are commonly utilized for conditions requiring swift relief, such as pain management, and for patients facing challenges with swallowing pills.

The primary types of oral transmucosal drugs include tablets, films, liquid formulations, sprays, and other related forms. Tablets within this category are solid dosage forms intended for administration through the mucous membranes in the mouth. They are indicated for various conditions such as opioid dependence, nausea and vomiting, erectile dysfunction, neurological disorders, and others, typically administered via the sublingual or buccal mucosa routes and distributed through hospital pharmacies, retail pharmacies, and online platforms.

The oral transmucosal drugs market research report is one of a series of new reports that provides oral transmucosal drugs market statistics, including oral transmucosal drugs industry global market size, regional shares, competitors with oral transmucosal drugs market share, detailed oral transmucosal drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the oral transmucosal drugs industry. This oral transmucosal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral transmucosal drugs market consists of sales of buccal patches, sublingual tablets, lozenges, and oral transmucosal powders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.